Abgenix strong buy rating

 focused exclusively on growth
 companies. In 1999, the firm completed 218 public offerings and 66
 private offerings, raising more
 than $40 billion in capital for clients. In addition, the firm advised on
 over 85 M&A transactions in
 1999 with an aggregate value in excess of $60 billion. The firm's 47
 equity research analysts cover
 nearly 700 companies. Founded in 1978, Robertson Stephens (Legal
 name: FleetBoston Robertson
 Stephens Inc.) is a section 20 subsidiary of FleetBoston Financial
 Corporation (NYSE: FBF -
 news) and a member of the NASD and all major exchanges.
 Together, Robertson Stephens,
 FleetBoston Robertson Stephens International Ltd., and Robertson
 Stephens Evergreen Securities
 Ltd. has over 1,000 employees worldwide with offices in Boston, San
 Francisco, New York,
 Menlo Park, Chicago, London, Munich and Tel Aviv.

 The following synopsis is qualified in its entirety by the more detailed
 information contained in the full
 research report, including the discussion of certain risks associated
 with an investment in this
 security contained in ``Investment Risks.''

 The information contained herein is not a complete analysis of every
 material fact respecting any
 company, industry or security. Although opinions and estimates
 expressed herein reflect the current
 judgment of BancBoston Robertson Stephens, the information upon
 which such opinions and
 estimates are based is not necessarily updated on a regular basis;
 when it is, the date of the change
 in estimate will be noted. In addition, opinions and estimates are
 subject to change without notice.
 This Report contains forward-looking statements, which involve risks
 and uncertainties. Actual
 results may differ significantly from the results described in the
 forward-looking statements. Factors
 that might cause such a difference include, but are not limited to,
 those discussed in ``Investment
 Risks.'' BancBoston Robertson Stephens from time to time performs
 corporate finance or other
 services for some companies described herein and may occasionally
 possess material, nonpublic
 information regarding such companies. This information is not used in
 the preparation of the opinions
 and estimates herein. While the information contained in this Report
 and the opinions contained
 herein are based on sources believed to be reliable, BancBoston
 Robertson Stephens has not
 independently verified the facts, assumptions and estimates
 contained in this Report. Accordingly,
 no representation or warranty, expressed or implied, is made as to,
 and no reliance should be
 placed on, the fairness, accuracy, completeness or correctness of
 the information and opinions
 contained in this Report. BancBoston Robertson Stephens, its
 managing directors, its affiliates,
 and/or its employees may have an interest in the securities of the
 issue(s) described and may make
 purchases or sales while this report is in circulation. BancBoston
 Robertson Stephens International
 Ltd. is regulated by the Securities and Futures Authority in the United
 Kingdom. This publication is
 not meant for private customers. The securities discussed herein are
 not FDIC insured, are not
 deposits or other obligations or guarantees of BankBoston N.A., and
 are subject to investment risk,
 including possible loss of any principal amount invested.

 Contact:

 Robertson Stephens, Inc.
 Elizabeth Denton, 202/326-1796
 biz.yahoo.com/bw/000307/ca_roberts_3.html
 culater



           

Bayer hat soviele Kooperationen mit Forschungseinrichtungen (Uni, Institute, Unternehmen), daß man dem Kooperationsvertrag zw. Bayer und Morphosys keine allzugroße Bedeutung beimessen darf!

Biotech findet in den USA statt!

Ich gönne wirklich jedem die Gewinne mit Morphosys, aber meine Meinung (und die muß nicht unbedingt die einzig richtige sein) ist, daß Morphosys eine heiße Kartoffel ist, die von Förtsch aufgrund von Performanceaspekten beim 3sat- Börsenspiel (Marktenge, Trendthema Biotech nach Internet, euer Markt) hochgejubelt und letztendlich für seine Zwecke (Popularitätsgewinn, Umsatzsteigerung der eigenen Infodienste) instrumentalisiert wird.

Ich sehe bei Morphosys nicht die Spur von Substanz!

Bist Du etwa Mediziner, oder was hat Dir die Erleuchtung zugetragen, sich lateinisch "Furz" zu nennen? Sehr witzig! HAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAH­AHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAH­AHAHAHAHAHHAHAHAHAHHAHAHHAHAHAHAH!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!­!!!

Die letzten 5 Trades zwischen 400-410$, ergo in Deutschland evtl. über 400 Euro.

Gruß TGK

schon zu der Erkenntnis geführt,dass dies eine Sackgasse sein kann und man auf jeden Fall auch menschliche Gene braucht.Kann es nicht sein,dass Abgenix reichlich überbewertet ist?Da sind doch jetzt nach der Erwähnung im Fernsehen massenhaft Daytrader drin.

Robertson Stephens Reiterates Strong Buy Rating on ABGX        TUESDAY, MARCH 21, 2000 12:01 PM
 - BusinessWire

SAN FRANCISCO, Mar 21, 2000 (BUSINESS WIRE) -- Robertson Stephens Managing Director and Senior Biopharmaceuticals Analyst Jay Silverman today reiterated his Strong Buy rating on Abgenix Inc. (NASDAQ:ABGX).
Abgenix is focused on the development and commercialization of proprietary monoclonal antibodies for pharmaceutical applications, including transplant related conditions, inflammation, autoimmune diseases and cancer.
"We are reiterating our Strong Buy rating on Abgenix," said Silverman. "Yesterday, the European Patent Office revoked broad claims in Protein Design Labs' (PDLI - $134) humanization patent. We believe the European Patent decision has negative implications for PDLI only and is totally unrelated to Abgenix."
"Abgenix patents on creating fully human antibodies via transgenic mice have never been challenged, nor do we expect them to be," said Silverman. "In fact, the majority of new antibodies under development since the XenoMouse became available are being developed by Abgenix and its partners. In our view, Abgenix is an excellent buying opportunity and we reiterate our Strong Buy rating."

Dennoch kann ich es einfach nicht glauben, wie ABGX von 420 auf 170 abgekackt ist.

Gruß
TGK

                    Wenn Antikörper nach beidseitiger Meinung eine klinische Untersuchung wert sind, wird von
                    beiden Parteien eine geschlossene Auktion durchgeführt, wonach sich entscheidet, wer die
                    Rechte zur Weiterentwicklung zu einem antikörper-basierten Produkt erhält. Die
                    meistbietende Gesellschaft muß das gebotene Entgelt an die andere Firma entrichten und
                    ist für alle weiteren Entscheidungen und Entwicklungskosten selbst verantwortlich. Die
                    nicht-entwickelnde Gesellschaft erhält einen Anteil von späteren Milestone Payments und
                    eine geringe Lizenzgebühr für zukünftige Produktverkäufe.

                    Die Zusammenarbeit wird von einem gemeinsamen Koordinationsausschuss gehandhabt,
                    der von einer gleichen Anzahl von Repräsentanten aus beiden Firmen gebildet wird. Der
                    Koordinationsausschuß ist für die Abnahme der Antigene von Corixa, für die
                    Betriebsmittelzuweisung und für die Bestimmung der am Auktionsprozess teilnehmenden
                    Antikörper verantwortlich.

                    Die Kurse der Aktien können von dieser Nachricht nicht profitieren. Abgenix notiert
                    momentan mit einem Minus von 11,4% bei 176 ¾ und Corixa mit –21% bei 40 US-Dollar.
                     
                    19:53 21.03, Stefan Ochsenkühn
                    © www.wallstreet-online.de


Ausserdem will Ich Abgenix kaufen und dieses sch.... Comdirekt lässt mich nicht rein!

Bei E-Net war auch unter
www.newsalert.com/bin/newsanal?Type=splits
ein Splitt drin, der jedoch nicht kam.

Grüsse, bilbo

Schau dir mal die Biotechs an der Nasdaq an die marschieren alle wieder nach  oben,der Turnaround ist nach meiner unbedeutenden Meinung geschafft die Chance Abgenix so billig zu bekommen ist bald vorbei!

Nach einem Absturz von 420 auf 157 $ denke ich, dass eine positive Gegenbewegung einsetzen könnte. TCLN und SCLN haben gestern ein nettes
Comeback gezeigt, bei ABGX ist es nur eine Frage der Zeit.

Dein Wort in Gottes Ohr MIKKA

TGK

found this in a maba press release.

"A recent study entitled "Therapeutic and Diagnostic Monoclonal Antibodies," published by Decision Resources, predicted that revenues from therapeutic monoclonal antibodies in seven major pharmaceutical markets (U.S., Japan and five European countries) will grow from about $500 million in 1998 to a total of $4.4 billion in 2008. Currently there are at least eight therapeutic antibodies sold in the US for a range of disorders including cardiovascular disease, cancer, and organ rejection. The Pharmaceutical Research and Manufacturers of America have reported that monoclonal antibodies comprised 20% of all biopharmaceuticals in clinical development in 1998."

this is why ABGX and MEDX are well positioned for future growth.

culater, you are the 4th person that has mentioned maba today! i might have to go with the mojo and buy some.
looks promising so far.  

ABGX verbleibt mind. noch 6 monate im Depot

Was hat du zur Zeit noch an Biotech-Werten ?

Gute Nacht
TGK

ich hatte mal Immune Response,danach hatte ich nicht den Mut,hat mich nur interessiert,aber schien mir alles viel zu rasant gestiegen.Immune Response werde ich mir vielleicht wieder holen,sind ja auch doll gefallen.

Hab´mich zwar vor ein paar Tagen ein bissl´weit aus dem Fenster gelehnt, aber langsam sollten wir den Boden gefunden haben nachdem Abgenix nochmal 30% verloren hat. Wenn sogar der Förtsch jetzt einen Biotech Wert von der Nasdaq kauft. Ausserdem schaut euch Ilex an sind am Freitag um 26% gestiegen an der Nasdaq.
Die Lichter scheinen doch langsam wieder auf grün zu stehen.
Good Trades
Mikka

Das Unternehmen hofft nach der Ausgabe von neuen Aktien im Februar, welche netto $496,5 Millionen einbrachte, jetzt ohne weitere Kapitalmaßnahmen für die Zukunft gerüstet zu sein. Es sollen nun ohne weitere Mittelzuflüsse positive Ergebnisse erwirtschaftet werden.

Abgenix startet Phase II Tests für ABX-IL8
von Redaktion WO 03.04.00 17:59:25
betrifft Aktie: ABGENIX INC.DL-,0001   744672

Abgenix Inc. (NASDAQ: ABGX) gab heute die Einleitung der Phase II der klinischen Studien für ABX-IL8 bekannt. In den multi-zentrierten, Placebo-kontrollierten Tests werden etwa 90 Patienten eingebunden, die an moderater bis harter Schuppenflechte leiden.

Erste Zwischenergebnisse werden zum Ende des Jahres erwartet. In Zukunft soll die Arznei auch in Phase II Tests zur Behandlung von rheumatischer Arthritis und Krebs geprüft werden.  

follow-on public offering. "In the first quarter of the new millennium, we continued to build and advance our proprietary product pipeline, expanded our roster of corporate collaborations and completed one of the largest public financings in the biotech industry," said R. Scott Greer, chairman and CEO of Abgenix. "We now have both the capital and the disease target sources to generate a continuing stream of antibody product candidates."

In other news, Abgenix announced today that R. Scott Greer, the company's president and chief executive officer, has been appointed chairman of the board of directors replacing Stephen A. Sherwin, M.D., who has served as chairman since the company's founding in 1996. Dr. Sherwin will continue as a director of the board.

"Dr. Sherwin, the chairman and chief executive officer of Cell Genesys, Inc., our parent company, played a key role in the development of our core business and was a co-founder of Abgenix," stated Mr. Greer. "We are grateful for his guidance as chairman over the past four years and look forward to his continuing service on our board of directors."

"The appointment of Scott Greer as chairman recognizes the strong leadership he has provided to Abgenix during its first four years," stated Dr. Sherwin. "During this time, Abgenix has carried out multiple successful financings, moved three products into clinical trials, and formed collaborations with eighteen companies."

Abgenix was created as a wholly owned subsidiary of Cell Genesys (Nasdaq:CEGE) in July 1996. Since its founding, Abgenix has raised over $900 million in private and public equity financings, including approximately $210 million for Cell Genesys. Currently, Cell Genesys owns approximately 12% of Abgenix's outstanding shares.

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company's Web site at www.abgenix.com.

Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.

                                                         Three months ended
                                                             March 31
                                                        2000           1999
   Revenues:                                                 (unaudited)
   Contract revenues                                   $1,965           $--
   Interest income                                      4,341           395
     Total revenues                                     6,306           395
   Costs and Expenses:
     Research and development                           7,214         4,567
     General and administrative                         1,584         1,084
     Amortization of intangible assets                    777            --
     Interest expense                                     114           133
     Equity in losses in Xenotech joint venture            --             8
       Total costs and expenses                         9,689         5,792
   Net loss                                          ($3,383)      ($5,397)

   Net loss per share*                                ($0.09)       ($0.22)
   Shares used in computing net loss per share*        37,250        24,274

                                                     March 31,   December 31,
   Balance Sheet                                       2000            1999
   (in thousands)                                   (unaudited)
   Cash, cash equivalents and
    marketable securities                            $568,003       $58,012
   Property and equipment, net                          5,253         5,300
   Long-term investment                                39,176        29,225
   Intangible assets, net                              45,814        46,591
   Other assets                                         4,825         9,413
   Total assets                                       663,071       148,541
   Deferred revenue                                    13,367         3,767
   Other current liabilities                            6,286         7,143
   Long-term debt and other                               296           571
   Stockholders' equity                               643,122       137,060
   Total liabilities and stockholders' equity        $663,071      $148,541

   * After giving effect to the two for one stock split effective
     April 6, 2000


Statements made in this press release about Abgenix's XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

SOURCE Abgenix, Inc.

(C) 2000 PR Newswire.  All rights reserved.
www.prnewswire.com
-0-
CONTACT:       Kurt Leutzinger, Chief Financial Officer of Abgenix Inc.,
              510-608-6575
              /Company News On-Call:  www.prnewswire.com/comp/126548.html or fax,
              800-758-5804, ext. 126548

WEB PAGE:      www.abgenix.com

GEOGRAPHY:     California

INDUSTRY CODE: MTC
              BIO

SUBJECT CODE:  ERN
              PER

Mit -0,09$ pro Aktie wurde die Whispernumber um 0,02$ getoppt

TGK

Hallo TGK!
Der Kursanstieg von Abgenix um 38% ist aber nur auf Xetra.Der Kurs an den Börsen liegt bei ca.90E.In den Staaten befindet sich die Aktie im Minus.
Da wir dem Ami oft hinterher laufen ,wird es morgen wieder interessant.

Gruß Imperator

Gegen Nas +4,5%


Abgenix and SB Enter XenoMouse Technology Collaboration SmithKline Becomes Nineteenth XenoMouse Partner
        FRIDAY, MAY 19, 2000 7:00 AM
 - PRNewswire

FREMONT, Calif., May 19, 2000 /PRNewswire via COMTEX/ -- Abgenix, Inc. (Nasdaq:ABGX) signed a collaboration agreement with SmithKline Beecham (SB) under which SB will use Abgenix's XenoMouse(TM) technology to generate fully human monoclonal antibodies to an undisclosed target. In return, Abgenix will receive a research license payment and could receive additional fees and milestone payments plus royalties on future product sales by SB. SB will be responsible for products developed through the collaboration.

"Abgenix is pleased to be collaborating with SB, one of the world's leading pharmaceutical companies," said R. Scott Greer, chairman, president and chief executive officer of Abgenix. "Acceptance of our XenoMouse human antibody technology continues to spread among pharmaceutical and biotechnology companies."

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company's Web site at www.abgenix.com.

Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.

Statements made in this press release about Abgenix's XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.


Vielleicht sattelt auch FLATUS auf das richtige Pferd um ??

TGK

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company's Web site at www.abgenix.com.

Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.

Statements made in this press release about Abgenix's XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

SOURCE Abgenix, Inc.

CONTACT:          Kurt Leutzinger, Chief Financial Officer of Abgenix, Inc.,
                 510-608-6575
                 /Company News On-Call:  www.prnewswire.com/comp/126548.html or fax,
                 800-758-5804, ext. 126548

URL:              www.abgenix.com
www.prnewswire.com


(C) 2000 PR Newswire. All rights reserved.


KEYWORD:          California
INDUSTRY KEYWORD: MTC
                 BIO
SUBJECT CODE:     LIC